Sign up Australia
Proactive Investors - Run By Investors For Investors

'We run Pressure BioSciences as if we were on Nasdaq or NYSE,' says CEO

With shrinking debt, the life-sciences company plans to uplist to a national exchange before year's end
a radio podcast app in smartphone
Schumacher appeared on the 'Stock Day Podcast' on Uptick Network Radio

Richard T Schumacher, CEO of Pressure BioSciences Inc (OTCMKTS:PBIO) said Monday that the company continues to strengthen its balance sheet by converting a “significant amount” of debt into equity.

He said that with shrinking debt, the life-sciences company plans to uplist to a national exchange before the end of the year.

“Although we are a QB company on the OTC Marketplace, we run the company as if we were NASDAQ or NYSE-Amex listed. This is important, since we have expectations of moving up to a national stock exchange before the end of this year,” Schumacher told the “Stock Day Podcast” on the Uptick Network Radio.  

The Harvard Medical School-trained serial entrepreneur said Pressure BioSciences has been “working diligently” to meet the requirements necessary to uplist to a national exchange.

On June 12, the company converted an additional US$7.24mln of debt into equity, bringing the total amount of debt that it has converted into equity over the past four weeks to more than US$13.6mln.

As a result of its move to pay down its debt and the bolster its revenue, the company’s finances are on more solid ground. 

READ: Pressure BioSciences invigorates its balance sheet, converts additional US$7.24mln of debt into equity

Pressure BioSciences was founded in 1978 and is based in South Easton, Massachusetts. It develops pressure cycling technology (PCT) solutions and is a leader in high pressure-based technologies, platforms, and services.

Hundreds of labs utilize the company's pressure-based systems to extract proteins carefully from cells and separate lipids, DNA, RNA and smart molecules from biological samples.

“We’re changing a paradigm that’s existed in labs for maybe 50 years,” said Schumacher.

Many other extraction methods used by over 500,000 researchers worldwide involve breaking cells open in more volatile ways that can actually damage the biomolecule contents or put researchers at risk.

PBI’s unique technology is more like squeezing a sponge, and the number of squeezes and level of pressure necessary for each unique cell type can be programmed into a computer that is part of their instrument. Individualizing profiles for human, plant, animal, and other normal or cancer cell types can promote consistency in research.

“High pressure has not really been utilized that much in the lab up to now, mainly because until we came along, there was really no way of safely getting high pressure into the lab,” Schumacher told the “Stock Day Podcast.” 

“We use pressures up to six times the pressure you would feel if you were standing at the bottom of Mariana’s Trench, with six miles of ocean on top of you. Now that is pressure,” he said.

Schumacher went on to tell the podcast that their pressure chambers can “safely reach levels up to 100,000 PSI, a staggering high” in the industry.

In 2017, the company pulled in revenue of $US2.24mln by selling 300 pressure cycling technology (PCT) machines to more than 175 customers.

However, 2018 is already shaping up as a banner year. The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

Investment case

The Stock Day Podcast host Everett Jolly noted that with a market cap of about US$4.2mln and shares selling at just under US$3 it was a “great time for investors” to get a look at Pressure BioSciences.

“It’s an extremely undervalued company. It’s one of those undiscovered gems for which investors are always looking. The company has done very well over the past 18-24 months, and we expect they will continue to do well, yet their stock price is actually down about 75% over that time. At some point, we believe they will be discovered,” said Jolly.

“Until then, in our opinion, the stock price is not even close to a true reflection of the value of this company.”

Shares of the company were up 2.56% to US$4 in morning trading.


View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use